With regard to CML, inhibition of the constitutive tyrosine kinase activity of p210 BCR-ABL [51] with imatinib alleviates the hyperproliferation-induced symptoms [52]. Here, EVPL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.